###begin article-title 0
Increased expression of FcgammaRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 457 465 <span type="species:ncbi:9606">patients</span>
The high-affinity receptor for IgG Fcgamma/CD64 is critical for the development of lupus nephritis (LN). Cross-linking Fc receptor on recruited monocytes by IgG-containing immune complexes is a key step in immune-complex-mediated nephritis in systemic lupus erythematosus (SLE). The goal of this study was to determine whether expression of Fc receptor (FcgammaR) I on circulating monocytes is associated with systemic inflammation and renal disease in SLE patients.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 19 27 <span type="species:ncbi:9606">patients</span>
We studied 205 SLE patients (132 with LN and 73 without LN) along with 74 healthy control individuals. Surface expression of CD14 (monocytes), FcgammaRI/CD64, FcgammaRII/CD32, and FcgammaRIII/CD16 was evaluated by flow cytometry. Monocyte function was assessed by determining the migratory capacity and the ability to produce CCL2 (monocyte chemotractic protein 1). High-sensitivity C-reactive protein, C3 and C4 were measured by nephelometry.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 409 417 <span type="species:ncbi:9606">patients</span>
There was little difference in the expression of FcgammaRIII/CD16 or FcgammaRIII/CD32 on circulating monocytes between patients with SLE and control individuals. In contrast, FcgammaRI/CD64 expression was significantly higher in SLE patients and even higher in patients with LN. FcgammaRI/CD64 expression was positively associated with serum creatinine and indicators of systemic inflammation. Monocytes from patients with high FcgammaRI/CD64 expression also exhibited increased chemotaxis and capacity to produce monocyte chemotractic protein 1.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 118 126 <span type="species:ncbi:9606">patients</span>
Increased FcgammaRI/CD64 expression on circulating monocytes parallels systemic inflammation and renal disease in SLE patients. We propose that circulating monocytes activated by immune complexes and/or proinflammatory mediators upregulate surface expression of FcgammaRI/CD64 in SLE. The enhanced chemotactic and inflammatory potential of the activated monocytes may participate in a vicious cycle of immune cell recruitment and renal injury in SLE.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 655 656 647 648 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 754 755 746 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 756 757 748 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies against a wide array of self-antigens [1]. Formation of immune complexes (ICs) between these autoantibodies and the target antigens has been linked to the development of lupus nephritis (LN) [2,3]. Deposition of ICs in the kidneys activates monocyte/macrophages by interacting with Fc receptor (FcgammaR) I and FcgammaRIII, initiating an inflammatory cascade of cytokines and chemokines. The release of proinflammatory mediators such as monocyte chemotractic protein 1 (MCP-1 (CCL2)), macrophage inflammatory protein 1 (CCL3) and fractalkine (CX3CL1) recruits monocyte/macrophages and other immune effector cells, culminating in tissue damage [4,5].
###end p 11
###begin p 12
###xml 177 178 169 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 455 456 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 805 806 773 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 56 61 <span type="species:ncbi:9606">human</span>
Three classes of FcgammaRs are expressed on circulating human monocytes. FcgammaRI/CD64 is a high-affinity receptor constitutively expressed at substantial levels by monocytes [6]. Monocytes also express high levels of FcgammaRII/CD32, a low-affinity receptor for ICs with two functionally distinct isoforms. In contrast, FcgammaRIII/CD16, a receptor with moderate affinity for complexed IgG, is present on only about 10% to 15% of circulating monocytes [7]. FcgammaRI, FcgammaRIIa and FcgammaRIII are activating Fc receptors bearing intracytoplasmic tyrosine-based activation motifs that trigger monocyte activation upon receptor aggregation. FcgammaRIIb, on the other hand, contains an immunoreceptor tyrosine-based inhibitory motif and functions as an inhibitory Fc receptor upon interacting with ICs [8].
###end p 12
###begin p 13
###xml 318 319 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 439 441 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 476 478 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 506 508 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 614 616 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
The balance of activating and inhibitory FcgammaR determines the magnitude of the cellular response in monocytes. Enhanced expression of activating FcgammaRs or decreased expression of the inhibitory FcgammaR can lower the activation threshold, leading to the production of inflammatory cytokines that may promote LN [9]. Conversely, NZB/W F1 mice deficient in FcgammaRI/III are protected from LN despite developing extensive IC deposits [10]. As in Wegener's granulomatosis [11] and rheumatoid arthritis [12], circulating monocytes in SLE are activated and exhibit increased surface expression of FcgammaRI/CD64 [13]. Whether this increase in activating FcgammaR on monocytes is related to development of LN, however, is unknown.
###end p 13
###begin p 14
###xml 59 64 <span type="species:ncbi:9606">human</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
To investigate the possible role of activating FcgammaR in human LN, we examined the expression of FcgammaRI/CD64, FcgammaRIII/CD16 and FcgammaRII/CD32 on circulating monocytes from SLE patients, and the relationship of FcgammaR expression levels to renal involvement and chemokine production.
###end p 14
###begin title 15
Materials and methods
###end title 15
###begin title 16
Study population
###end title 16
###begin p 17
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 776 777 776 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 167 175 <span type="species:ncbi:9606">patients</span>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
###xml 354 361 <span type="species:ncbi:9606">patient</span>
###xml 373 385 <span type="species:ncbi:9606">participants</span>
The present study was approved by the University of Florida Institutional Review Board, and all subjects provided written informed consent prior to participation. SLE patients met at least four of the revised 1982 American College of Rheumatology criteria [14]. Peripheral blood was collected from 205 patients and 74 healthy control individuals. In the patient group, 132 participants had either biopsy-proven or laboratory-proven LN and 73 had no evidence of LN. At each visit a medication history and key laboratory parameters were collected. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index [15]. Detailed demographics, clinical characteristics, medication usage and laboratory measurements for all groups are presented in Table 1.
###end p 17
###begin p 18
###xml 73 85 <span type="species:ncbi:9606">participants</span>
Demographics, laboratory characteristics and clinical characteristics of participants
###end p 18
###begin p 19
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 126 128 126 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 245 251 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 251 253 246 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 263 275 258 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;&#8224;</sup>
###xml 275 277 260 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
aPresence of specific manifestations at any point during the course of disease. bMedication usage at the time of this study. *P < 0.05 for systemic lupus erythematosus (SLE) patients with or without lupus nephritis (LN) versus healthy controls. daggerP < 0.05 or daggerdaggerP < 0.001 for SLE patients with LN versus SLE patients without LN.
###end p 19
###begin title 20
Cell surface staining
###end title 20
###begin p 21
###xml 574 576 571 573 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 628 629 625 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
Antibodies were obtained from BD Pharmingen (San Diego, CA, USA) unless indicated otherwise. Heparinized whole blood (100 mul) was stained with PerCP-conjugated anti-CD14 (clone MPhi P9), fluorescein isothiocyanate-conjugated anti-CD16 (clone 3G8), allophycocyanin-conjugated anti-CD32 (clone FLI8.26), anti-HLA-DR (clone LN3), anti-CD62L (clone DREG56; eBioscience, San Diego, CA, USA), phycoerythrin-conjugated anti-CD64 (clone X54-5/7.1.1), and anti-CD16 (clone 3G8) for 30 minutes in the dark. Following lysis of erythrocytes, cells were washed with PBS/1% BSA/0.01% NaN3 and were fixed in 2% paraformaldehyde PBS. Cells (105) were analyzed using a FACSCalibur flow cytometer and CellQuest software (Becton Dickinson, Mountain View, CA, USA).
###end p 21
###begin p 22
Gates were set around monocytes based on their forward/sideward light scatter pattern and CD14 expression. Surface marker expression levels were expressed as the geometrical mean fluorescence intensity on monocytes. Since not all CD14 monocytes express CD16, CD32, CD62L and HLA-DR, expression was also expressed as the percentage of positive monocytes. Data analysis was performed using FCS Express 2.0 (De Novo Software, Thornhill, ON, Canada).
###end p 22
###begin title 23
Analysis of chemokine production
###end title 23
###begin p 24
###xml 205 221 205 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 526 528 511 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 107 113 <span type="species:ncbi:9913">bovine</span>
###xml 205 221 <span type="species:ncbi:562">Escherichia coli</span>
###xml 319 324 <span type="species:ncbi:9606">human</span>
###xml 1308 1313 <span type="species:ncbi:10090">mouse</span>
Heparinized whole blood was diluted 1:1 with DMEM (Mediatech, Inc., Herndon, VA, USA) containing 10% fetal bovine serum (Mediatech, Inc.), and was stimulated with lipopolysaccharide (LPS) (500 ng/ml, from Escherichia coli; Sigma Chemical Company, St Louis, MO, USA) or C-reactive protein (CRP) (50 ng/ml, purified from human serum, endotoxin-free; Calbiochem, La Jolla, CA, USA) in the presence of the protein transport inhibitor GolgiStoptrade mark (BD Pharmingen). In all cases, cells were incubated at 37degreesC in a 5% CO2 atmosphere for 4 hours. The dose of LPS and CRP and the length of incubation were optimized for chemokine production in preliminary experiments. Immediately after incubation, 100 mul aliquots of cells were stained with appropriate combinations of monoclonal antibodies for 30 minutes at 22degreesC in the dark. After incubation, 2 ml PharMlyse (BD Pharmingen) was added to lyse erythrocytes. After washing, cells were fixed and permeabilized with 200 mul Cytofix/Cytoperm solution (BD Pharmingen) for 20 minutes at 4degreesC. After two washes with Perm/Wash solution (BD Pharmingen), cells were resuspended in 100 mul Perm/Wash solution containing 1.5 mug/mul phycoerythrin-conjugated anti-MCP-1 clone (5D3-F7; BD Pharmingen) or the same concentration of phycoerythrin-conjugated mouse IgG1 as an isotype control. After incubating at 4degreesC for 30 minutes in the dark, cells were washed and analyzed by flow cytometry.
###end p 24
###begin title 25
Chemotaxis assay
###end title 25
###begin p 26
###xml 252 254 252 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7 </sup>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 215 221 <span type="species:ncbi:9913">bovine</span>
Peripheral blood mononuclear cells isolated from SLE patients and from healthy control individuals using Ficoll-Hypaque density gradient centrifugation were washed once and resuspended in DMEM containing 0.5% fetal bovine serum at a concentration of 107 cells/ml. Medium containing MCP-1 (25 ng/ml; Research Diagnostics Inc., Flanders, NJ, USA) or medium alone as a control were added to the lower chambers of a 24-well Costar Transwell plate (Corning Inc. Corning, NY, USA). The cell suspension (100 mul) was added to the upper chamber, which was separated from the lower chamber by a polycarbonate membrane (8.0 mum pores). After incubation for 3 hours at 37degreesC, cells in the lower chamber were collected, stained with anti-CD14, anti-CD16, and anti-HLA-DR, and analyzed by flow cytometry. Results are presented as a migration index calculated by dividing the number of cells that migrated toward MCP-1 by the number of cells that migrated to medium alone.
###end p 26
###begin title 27
Measurement of C-reactive protein and complement
###end title 27
###begin p 28
###xml 87 91 87 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 163 165 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
High-sensitivity C-reactive protein, C3 and C4 assays were performed using a BN ProSpec(R) Nephelometer (Dade Behring, Deerfield, IL, USA) as described elsewhere [16].
###end p 28
###begin title 29
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
In vitro stimulation of healthy donor peripheral blood mononuclear cells
###end title 29
###begin p 30
###xml 101 103 101 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 188 189 188 189 <sc xmlns:xlink="http://www.w3.org/1999/xlink">L</sc>
###xml 674 677 659 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5 </sup>
###xml 682 685 667 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-3 </sup>
###xml 168 174 <span type="species:ncbi:9913">bovine</span>
###xml 398 403 <span type="species:ncbi:9606">human</span>
Peripheral blood mononuclear cells from healthy control individuals were plated on 24-well plates (106 cells/well) in complete medium (DMEM supplemented with 10% fetal bovine serum, 20 mM L-glutamine, 100 IU/ml penicillin, and 100 mug/ml streptomycin). All cytokines were from BD Bioscience unless indicated otherwise. Cells were incubated for 19 hours at 37degreesC in the presence of recombinant human IFNalpha (4 ng/ml; PBL Biomedical, Piscataway, NJ, USA), IFNgamma (2 ng/ml), IL-4 (4 ng/ml), IL-6 (4 ng/ml), IL-8 (4 ng/ml), IL-12 (4 ng/ml), or CRP (50 ng/ml; Calbiochem). Flow cytometry was performed immediately after incubation. In some experiments, dexamethasone (10-5 to 10-3 M) was added to the culture 3 hours prior to the addition of cytokines.
###end p 30
###begin title 31
Statistical analysis
###end title 31
###begin p 32
###xml 108 110 108 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 193 195 193 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 466 468 464 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Differences between disease groups and normal control individuals were evaluated using Student's two-tailed t test unless the data were not normally distributed, in which case the Mann-Whitney U test was used. Correlation coefficients were calculated using Spearman's rank correlation. Data are presented as the mean +/- standard error of the mean. Analyses were performed using Prism software, version 4.0 (GraphPad Software, San Diego, CA, USA). For all analyses, P < 0.05 was considered significant.
###end p 32
###begin title 33
Results
###end title 33
###begin p 34
###xml 202 203 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 266 268 262 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 356 357 352 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 598 600 585 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 619 621 606 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 290 298 <span type="species:ncbi:9606">patients</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
We assessed the surface expression of FcgammaRs on monocytes from SLE patients with or without LN and from healthy control individuals. Demographics and clinical/laboratory data are summarized in Table 1. There was no difference in the percentage of circulating CD14+ monocytes between SLE patients with or without LN and normal control individuals (Table 2). Absolute monocyte counts, however, were significantly decreased in SLE patients with/without LN when compared with normal control individuals (268 +/- 29 cells/mul and 254 +/- 39 cells/mul, respectively, versus 357 +/- 32 cells/mul; both P < 0.005, Student's t test).
###end p 34
###begin p 35
###xml 52 54 52 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Comparison of cell surface marker expression by CD14+ monocytes
###end p 35
###begin p 36
###xml 1 3 1 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 15 17 15 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 146 152 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 152 154 147 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 164 176 159 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;&#8224;</sup>
###xml 176 178 161 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
*P < 0.05 or **P < 0.001 for systemic lupus erythematosus (SLE) patients with or without lupus nephritis (LN) versus healthy control individuals. daggerP < 0.05 or daggerdaggerP < 0.001 for SLE patients with LN versus SLE patients without LN.
###end p 36
###begin title 37
Increased FcgammaRI/CD64 expression on SLE monocytes
###end title 37
###begin p 38
###xml 226 228 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 244 245 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 345 347 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 549 551 523 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 570 572 544 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 706 708 676 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 727 729 697 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 743 745 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 756 757 726 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 288 296 <span type="species:ncbi:9606">patients</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
###xml 613 621 <span type="species:ncbi:9606">patients</span>
In healthy control individuals, nearly all peripheral blood monocytes displayed surface expression of FcgammaRI/CD64 and FcgammaRII/CD32. Only 9.3 +/- 0.7% of circulating monocytes, however, expressed FcgammaRIII/CD16 (Figure 1a, top and Table 2). Although circulating monocytes from SLE patients also uniformly expressed FcgammaRI/CD64 (Figure 1a, bottom), quantification of FcgammaRI/CD64 expression showed a significantly higher mean fluorescence intensity in SLE patients compared with healthy control individuals (521 +/- 21 versus 319 +/- 22; P < 0.001, Student's t test). The expression was even higher in patients with nephritis compared with those without nephritis (567 +/- 28 versus 449 +/- 31; P < 0.001, Student's t test) (Figure 1b and Table 2).
###end p 38
###begin p 39
###xml 0 102 0 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of Fc receptors in healthy control individuals versus systemic lupus erythematosus patients</bold>
###xml 104 108 104 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 221 223 209 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 341 343 329 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 405 408 393 396 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b-</bold>
###xml 408 411 396 399 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d) </bold>
###xml 691 693 667 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 699 703 675 679 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 879 881 851 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 937 939 909 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 279 286 <span type="species:ncbi:9606">patient</span>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
###xml 771 779 <span type="species:ncbi:9606">patients</span>
###xml 906 914 <span type="species:ncbi:9606">patients</span>
Expression of Fc receptors in healthy control individuals versus systemic lupus erythematosus patients. (a) Representative scattergrams of surface expression of FcgammaRI/CD64, FcgammaRII/CD32 and FcgammaRIII/CD16 on CD14+ monocytes from a healthy control individual (top) and a patient with systemic lupus erythematosus (SLE) (bottom). CD14+ monocytes were gated based on their forward/sideward scatter. (b-d) Expression of FcgammaRI/CD64, FcgammaRII/CD32 and FcgammaRIII/CD16, respectively (mean fluorescence intensity (MFI)) on SLE versus control monocytes. SLE patients with and without lupus nephritis (LN) are analyzed separately. Differences between groups were compared by Student's t test. (e) Comparison of FcgammaRI/CD64 expression (MFI) on monocytes from SLE patients without LN or with biopsy-proven World Health Organization class II, class III/IV, or class V LN. *P < 0.05 compared with SLE patients without LN (Student's t test).
###end p 39
###begin p 40
###xml 48 50 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 195 196 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 200 202 200 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 446 448 440 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 466 468 460 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 482 484 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 495 496 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
In contrast, CD32 expression was similar on CD14+ monocytes from SLE patients versus normal healthy control individuals (Figure 1c and Table 2). While the frequencies and absolute numbers of CD16+CD14+ monocytes were similar between SLE patients and control individuals, the intensity of CD16 staining was increased slightly in SLE patients with or without LN (12 +/- 0.4 and 13 +/- 0.6, respectively, versus control individuals 10 +/- 0.6; both P < 0.01, Student's t test) (Figure 1d and Table 2). We also assessed the expression of HLA-DR and CD62L, markers related to monocyte activation, but found no significant differences between the groups (data not shown).
###end p 40
###begin p 41
###xml 416 418 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1e</xref>
###xml 132 140 <span type="species:ncbi:9606">patients</span>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
To further evaluate the relationship between FcgammaR expression and LN, we analyzed the expression of FcgammaRs on monocytes in 79 patients who had undergone renal biopsy (class II, n = 7; class III/IV, n = 43; and class V, n = 29). The presence of class III/IV or class V LN, but not of class II LN, was associated with increased expression of FcgammaRI/CD64 compared with SLE patients who did not have LN (Figure 1e). In contrast, the expression of FcgammaRII and FcgammaRIII was similar among the different classes of LN (data not shown).
###end p 41
###begin title 42
Increased FcgammaRI/CD64 expression is associated with impaired renal function
###end title 42
###begin p 43
###xml 299 300 291 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 300 302 292 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 310 312 302 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 353 355 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 395 396 387 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 396 398 388 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 406 408 398 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 449 451 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 536 537 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 537 539 529 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 547 549 539 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 590 592 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
Since FcgammaRI/CD64 expression on monocytes was greater in SLE patients with LN compared with SLE patients without LN, we investigated its relationship with individual markers of renal involvement. Increased expression of FcgammaRI/CD64 on monocytes correlated positively with elevated creatinine (r2 = 0.27, P < 0.001; Spearman's correlation) (Figure 2a, left) and blood urea nitrogen levels (r2 = 0.12, P = 0.001; Spearman's correlation) (Figure 2a, middle), as well as with the degree of proteinuria (microalbumin/creatinine ratio, r2 = 0.10, P < 0.001; Spearman's correlation) (Figure 2a, right).
###end p 43
###begin p 44
###xml 0 114 0 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fc&#947;RI/CD64 expression on monocytes correlates with renal disease, C-reactive protein, and complement C3 levels</bold>
###xml 116 120 112 116 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 508 512 496 500 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 589 593 577 581 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 651 655 639 643 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 773 775 757 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
###xml 702 710 <span type="species:ncbi:9606">patients</span>
FcgammaRI/CD64 expression on monocytes correlates with renal disease, C-reactive protein, and complement C3 levels. (a) FcgammaRI/CD64 expression levels on circulating monocytes from systemic lupus erythematosus (SLE) patients (both lupus nephritis (LN) and non-LN patients) correlated with increased serum creatinine (left) and blood urea nitrogen (BUN) (middle), as well as with proteinuria (microalbumin/creatinine ratio) (right). MFI, mean fluorescence intensity. Expression of FcgammaRI/CD64 correlated (b) positively with serum high-sensitivity C-reactive protein (HsCRP) levels and (c) negatively with serum C3 levels (Spearman's correlation). (d) Comparison of FcgammaRI/CD64 expression in SLE patients positive or negative for anti-dsDNA autoantibodies (Student's t test).
###end p 44
###begin title 45
Increased levels of FcgammaRI/CD64 expression are associated with ongoing inflammation
###end title 45
###begin p 46
###xml 150 152 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 301 302 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 302 304 294 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 312 314 304 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 356 358 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 433 434 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 434 436 422 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 444 446 432 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 488 490 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c</xref>
###xml 509 510 497 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 510 512 498 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 520 522 508 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 708 710 688 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 728 730 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2d</xref>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
###xml 929 937 <span type="species:ncbi:9606">patients</span>
We next examined the relationship of FcgammaRI/CD64 expression with measures of systemic inflammation such as high-sensitivity CRP and complement C3 [17]. In patients with SLE, the expression of FcgammaRI/CD64 on monocytes was positively correlated with elevated serum levels of high-sensitivity CRP (r2 = 0.14, P < 0.0001; Spearman's correlation) (Figure 2b). FcgammaRI/CD64 expression showed an inverse relationship with serum C3 (r2 = 0.07, P < 0.0001; Spearman's correlation) (Figure 2c) but not with C4 (r2 = 0.01, P = 0.14) (data not shown). Increased FcgammaRI/CD64 expression was also associated with anti-dsDNA autoantibodies (534.1 +/- 21.4 versus 426.5 +/- 21.0 mean fluorescence intensity units, P = 0.0005) (Figure 2d). Increased FcgammaRI/CD64 surface expression on monocytes was therefore associated with impaired renal function, anti-dsDNA autoantibody production, C3 consumption, and ongoing inflammation in SLE patients.
###end p 46
###begin title 47
###xml 13 16 9 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi </sup>
FcgammaRI/CD6hi monocytes have an activated phenotype
###end title 47
###begin p 48
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 241 250 241 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 390 391 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 391 393 387 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 401 403 397 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 444 446 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
Monocyte migration to the kidneys and the subsequent release of inflammatory mediators are thought to be critical steps initiating renal damage [18,19]. We evaluated the migratory capacity of circulating monocytes from SLE patients using an in vitro transwell assay, and found that monocytes with elevated FcgammaRI/CD64 expression exhibited increased migration toward the chemokine MCP-1 (r2 = 0.09, P = 0.005; Spearman's correlation) (Figure 3a).
###end p 48
###begin p 49
###xml 14 17 10 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">hi </sup>
###xml 0 54 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Fc&#947;RI/CD64<sup>hi </sup>monocytes have an activated phenotype</bold>
###xml 56 60 52 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 247 251 239 243 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 404 406 392 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 502 506 490 494 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
FcgammaRI/CD64hi monocytes have an activated phenotype. (a) Correlation between FcgammaRI/CD64 expression levels and monocyte migration toward monocyte chemotractic protein 1 (MCP-1) (transwell assay, systemic lupus erythematosus (SLE) patients). (b) Correlation of elevated FcgammaRI/CD64 expression on monocytes with an increased capacity to produce MCP-1, as measured by intracellular staining of CD14+ monocytes 4 hours after lipopolysaccharide (LPS) stimulation. MFI, mean fluorescence intensity. (c) Correlation of FcgammaRI/CD64 expression with levels of MCP-1 production by monocytes following C-reactive protein (CRP) stimulation for 4 hours.
###end p 49
###begin p 50
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 196 198 196 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 344 346 340 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 396 397 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 397 399 393 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 407 409 403 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 450 452 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
As monocyte-derived proinflammatory cytokines and chemokines such as MCP-1 regulate immune cell infiltration and play an important role in organ damage in SLE [20], we examined the ability of CD64+ monocytes to produce MCP-1. After LPS stimulation, monocytes with high FcgammaRI/CD64 expression produced higher levels of the chemokine than CD64- monocytes, as measured by intracellular staining (r2 = 0.09, P < 0.001; Spearman's correlation) (Figure 3b).
###end p 50
###begin p 51
###xml 121 123 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 124 126 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 310 312 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 324 326 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 499 500 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 500 502 488 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 510 512 498 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 552 554 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c</xref>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
Since the binding of CRP to FcgammaRI/CD64 and FcgammaRIIa/CD32a can lead to increased inflammatory cytokine production [21-23], we stimulated monocytes from SLE patients with CRP (50 ng/ml) and analyzed the MCP-1 production. CRP and LPS elicited similar levels of intracellular MCP-1 staining (compare Figure 3b and Figure 3c). Consistent with the results with LPS stimulation, high FcgammaRI/CD64 surface expression was associated with increased intracellular MCP-1 production in response to CRP (r2 = 0.26, P = 0.03; Spearman's correlation) (Figure 3c). Monocytes with elevated surface expression of FcgammaRI/CD64 therefore displayed a more activated phenotype in terms of migratory properties and MCP-1 production in response to either LPS or CRP.
###end p 51
###begin title 52
Medication effects on FcgammaRI/CD64 expression
###end title 52
###begin p 53
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 497 499 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 620 622 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 791 793 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 933 935 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 1069 1071 1045 1047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1161 1163 1133 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
###xml 447 455 <span type="species:ncbi:9606">patients</span>
###xml 637 645 <span type="species:ncbi:9606">patients</span>
###xml 938 946 <span type="species:ncbi:9606">Patients</span>
Corticosteroids potently downmodulate certain inflammatory markers on circulating monocytes [24]. Since about one-half of our SLE patients were treated with corticosteroids (Table 1), we asked whether the levels of FcgammaRI/CD64 expression by monocytes were affected by treatment. When analyzed as a group, patients treated with conventional doses of prednisone (< 40 mg/day) showed no difference in FcgammaRI/CD64 expression compared with those patients not treated with corticosteroids (Figure 4a). There also was no apparent effect of antimalarial, cytotoxic or statin therapy on the expression of FcgammaRs (Figure 4a). Stratifying patients based on the prednisone dose revealed that a daily dosage >/= 40 mg was associated with decreased FcgammaRI/CD64 expression on monocytes (Figure 4b). A similar trend (not statistically significant) was seen at a dose of 20 to 30 mg/day. This effect was not seen at lower dosages (Figure 4b). Patients treated with >/= 40 mg/day prednisone tended to display lower serum levels of C3 (67.6 +/- 8.5 versus 93.7 +/- 3.4 mg/dl; P < 0.05) and higher levels of blood urea nitrogen (36.9 +/- 9.0 versus 15.6 +/- 0.8 ng/dl; P < 0.05) compared with their counterparts given lower doses, consistent with higher disease activity (data not shown). There was no difference in Systemic Lupus Erythematosus Disease Activity Index scores, American College of Rheumatology criteria counts, serum creatinine, high-sensitivity CRP levels, or microalbumin/creatinine ratios between the groups (data not shown).
###end p 53
###begin p 54
###xml 0 89 0 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of medications and cytokines on Fc&#947;RI/CD64 expression by circulating monocytes</bold>
###xml 91 95 87 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 317 321 309 313 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 425 427 413 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 414 422 <span type="species:ncbi:9606">patients</span>
###xml 452 460 <span type="species:ncbi:9606">patients</span>
Effect of medications and cytokines on FcgammaRI/CD64 expression by circulating monocytes. (a) Comparison of FcgammaRI/CD64 expression on monocytes between systemic lupus erythematosus (SLE) patients receiving or not receiving prednisone, antimalarials, cytotoxic drugs, or statins. MFI, mean fluorescence intensity. (b) Relationship between daily corticosteroid dose and monocyte FcgammaRI/CD64 expression in SLE patients. *P < 0.05 compared with SLE patients not receiving steroid treatment.
###end p 54
###begin title 55
Effect of cytokines on FcgammaRI/CD64 expression
###end title 55
###begin p 56
###xml 588 590 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
Several studies have shown that the expression of FcgammaRI/CD64 can be influenced by different cytokines in pathogenic circumstances. Dysregulation of proinflammatory cytokine production has also been well documented in SLE. To examine potential inducers of FcgammaRI/CD64 upregulation, we stimulated peripheral blood mononuclear cells from healthy control individuals with a panel of cytokines. Overnight incubation with IFNalpha, IFNgamma, and IL-12 significantly increased FcgammaRI/CD64 expression on monocytes, whereas IL-6, IL-8, IL-10, TNFalpha, and CRP treatment did not (Figure 5a). Similar results were obtained when the experiment was performed using cultured THP-1 cells (data not shown).
###end p 56
###begin p 57
###xml 67 75 63 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 0 75 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of cytokines and dexamethasone on Fc&#947;RI/CD64 expression <italic>in vitro</italic></bold>
###xml 77 81 73 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 416 424 400 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 619 621 597 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 657 661 635 639 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 723 731 697 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 803 807 775 779 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
Effect of cytokines and dexamethasone on FcgammaRI/CD64 expression in vitro. (a) Direct effects of cytokines and C-reactive protein (CRP) on FcgammaRI/CD64 expression on circulating monocytes. Peripheral blood mononuclear cells from healthy subjects were cultured with recombinant IFNalpha (4 ng/ml), IFNgamma (2 ng/ml), IL-4 (4 ng/ml), IL-6 (4 ng/ml), IL-8 (4 ng/ml), IL-12 (4 ng/ml) or CRP (50 ng/ml) for 19 hours in vitro. FcgammaRI/CD64 expression (mean fluorescence intensity (MFI)) was analyzed by flow cytometry. Values represent the mean +/- standard error of the mean (SEM) from five independent experiments. *P < 0.001 compared with medium alone. (b) Effect of dexamethasone on monocyte FcgammaRI/CD64 expression in vitro. Values represent the mean +/- SEM from three independent experiments. (c) Effect of dexamethasone on the upregulation of FcgammaRI/CD64 by IFNalpha, IFNgamma, and IL-12. Values represent the mean +/- SEM from two independent experiments.
###end p 57
###begin p 58
###xml 142 151 138 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 159 161 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 208 211 202 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-4 </sup>
###xml 318 320 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
Curiously, while the addition of dexamethasone to whole blood did not alter the steady-state levels of FcgammaRI/CD64 expression on monocytes in vitro (Figure 5b), high concentrations of dexamethasone (>/= 10-4 M) inhibited the upregulation of FcgammaR1/CD64 expression induced by IFNgamma, IFNalpha and IL-12 (Figure 5c). This effect was not seen with lower concentrations of dexamethasone.
###end p 58
###begin title 59
Discussion
###end title 59
###begin p 60
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 3 8 <span type="species:ncbi:10090">mouse</span>
###xml 208 213 <span type="species:ncbi:9606">human</span>
###xml 318 323 <span type="species:ncbi:9606">human</span>
###xml 353 358 <span type="species:ncbi:10090">mouse</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
###xml 545 553 <span type="species:ncbi:9606">patients</span>
In mouse models of SLE, monocytes/macrophages bearing activating Fc receptors are pivotal to the development of IC-mediated glomerulonephritis [25,26]. There is indirect evidence that the same may be true of human lupus [27,28], although the relationship between activating FcgammaR expression and the pathogenesis of human LN is less clear than in the mouse. In the present study, we examined FcgammaR expression in more than 200 SLE patients. The levels of FcgammaRI/CD64 expression on circulating monocytes were significantly elevated in SLE patients, especially in those with LN. Increased monocyte FcgammaRI/CD64 expression also was associated with markers of impaired renal function impairment and with a greater ability to migrate and secrete the chemokine MCP-1.
###end p 60
###begin p 61
###xml 207 209 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 357 359 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 518 520 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 521 523 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
###xml 512 516 <span type="species:ncbi:10090">mice</span>
The proinflammatory role of activating FcgammaR in LN is evident in mice deficient in FcgammaRI/III, which are protected from the development of renal disease despite the presence of glomerular IC deposits [10]. A recent study showed that the expression of FcgammaRI/III by monocytes was both necessary and sufficient to trigger nephritis in NZB/W F1 mice [26]. In contrast, the inhibitory FcgammaRIIb suppresses inflammation and spontaneous activation of autoreactive lymphocytes and autoantibody production in mice [26,29].
###end p 61
###begin p 62
###xml 112 114 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 115 117 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 287 289 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 542 544 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 545 547 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
###xml 637 645 <span type="species:ncbi:9606">patients</span>
###xml 702 708 <span type="species:ncbi:10090">murine</span>
In human SLE, several groups have shown the abnormal upregulation of activating Fcgamma receptors on monocytes [13,30]. One relatively small study, however, found no significant difference in FcgammaRI/CD64 or FcgammaRIII/CD16 expression on SLE monocytes compared with healthy controls [31]. About two-thirds of the patients studied here had elevated levels of monocyte surface CD64 in the present study, a discrepancy that may be due to the relatively small number of subjects studied previously. Consistent with the observations of others [13,28], our data show that the activating receptor FcgammaRIII/CD16 also is upregulated in SLE patients compared with healthy control individuals. In line with murine lupus data, our data support the idea that activating FcgammaRs play a crucial role in IC-mediated organ damage in SLE.
###end p 62
###begin p 63
###xml 915 917 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 442 447 <span type="species:ncbi:9606">human</span>
###xml 559 567 <span type="species:ncbi:9606">patients</span>
###xml 853 861 <span type="species:ncbi:9606">patients</span>
###xml 1052 1060 <span type="species:ncbi:9606">patients</span>
Although NZB/W F1 mice deficient in activating FcgammaRs are protected from renal disease, the relative contributions of the individual activating FcgammaRs have not been studied further. Our data show that although both FcgammaRIII/CD16 and FcgammaRI/CD64 expression were elevated, increased FcgammaRIII/CD16 expression was not associated with LN, suggesting that activation via FcgammaRI/CD64 may be more significant to the pathogenesis of human LN. Moreover, we found no difference in the surface expression of FcgammaRII/CD32 on monocytes between the SLE patients and healthy control individuals, although interpretation of this finding is limited by the inability of the anti-CD32 antibody to distinguish the activating FcgammaRIIa and inhibitory FcgammaRIIb. Expression of the inhibitory FcgammaRIIb in peripheral blood mononuclear cells from SLE patients has been recently studied using specific antibodies [32]. While low expression levels were found on B-lymphocyte subsets, FcgammaRIIb/CD32b expression was not impaired on monocytes from SLE patients.
###end p 63
###begin p 64
###xml 311 313 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 314 316 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 402 404 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 405 407 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 525 527 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
The importance of FcgammaRs in the pathogenesis of SLE is further illustrated by extensive polymorphism studies involving FcgammaRII/CD32 and FcgammaRIII/CD16. Several of these polymorphisms - including FcgammaRIIa-131R, FcgammaRIIIa-176F, and FcgammaRIIIb-NA2 - have been associated with lupus susceptibility [33,34]. Importantly, some of them cause functional alterations of the inhibitory receptor [35,36] while others are associated with reduced surface expression of FcgammaRIIb on both memory and plasma B lymphocytes [37]. To our knowledge, however, polymorphisms involving FcgammaRI/CD64 have not been linked to SLE.
###end p 64
###begin p 65
###xml 86 88 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 800 809 786 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 915 917 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 918 920 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1006 1008 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1009 1011 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
The markedly elevated expression of FcgammaRI/CD64 among SLE patients with LN (Figure 1b) may serve as a surrogate marker of renal disease that correlates with both established measures of renal dysfunction (increased serum creatinine, blood urea nitrogen, and proteinuria) and inflammation (elevated serum CRP, C3 deficiency). Monocyte FcgammaRI/CD64 expression, however, did not correlate with overall disease activity as assessed by the Systemic Lupus Erythematosus Disease Activity Index (data not shown). This was not due to medication use, since FcgammaRI/CD64 levels on circulating monocytes were unaffected by treatment with prednisone at doses < 40 mg/day, or by antimalarials, cytotoxic agents, or statins. In contrast, higher doses of prednisone (>/= 40 mg/day) or dexamethasone treatment in vitro reduced FcgammaRI/CD64 expression, possibly due to direct effects on proinflammatory cytokine production [38,39] or to the generation of a subset of anti-inflammatory monocytes that secrete IL-10 [40,41].
###end p 65
###begin p 66
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 207 209 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 210 212 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 307 309 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 310 312 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 395 397 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 568 569 541 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 769 770 738 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 777 778 746 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 778 780 747 749 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1067 1073 1028 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vitro </italic>
###xml 201 205 <span type="species:ncbi:10090">mice</span>
###xml 218 223 <span type="species:ncbi:9606">human</span>
Our in vitro data suggest that IL-12, IFNgamma, and IFNalpha are potential inducers of FcgammaRI/CD64 expression in SLE. Interestingly, excess production of all three of these cytokines promotes LN in mice [42-44]. In human LN, increased levels of IFNgamma, IL-12 and IFNalpha/beta are found in the kidney [45,46]. Dysregulation of IFNalpha production is also associated with renal involvement [47]. Our data are consistent with the possibility that the overproduction of one or more of these cytokines promotes LN by enhancing the recruitment of proinflammatory (CD64+) monocytes/macrophages to the renal glomerulus. Although there was a highly significant correlation between FcgammaRI/CD64 expression and several markers of renal involvement or inflammation (Figure 2), the r2 values were in some cases relatively low. This indicated the existence of additional variables, at present undefined, affecting FcgammaRI/CD64 expression. Elucidating the variables that affect FcgammaRI/CD64 expression, perhaps including serum levels of the cytokines examined in our in vitro studies, will require further study.
###end p 66
###begin p 67
###xml 222 224 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 630 632 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 633 635 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 771 773 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 774 776 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 297 302 <span type="species:ncbi:9606">human</span>
###xml 318 326 <span type="species:ncbi:9606">patients</span>
###xml 605 610 <span type="species:ncbi:9606">human</span>
FcgammaRI/CD64 plays a role in phagocytosis, cytolysis, degranulation, and induction of inflammatory cytokines. Additionally, FcgammaRI-deficient mice display defective peritoneal monocyte infiltration in response to ICs [48]. Consistent with these studies, our data demonstrated that circulating human monocytes from patients with upregulated FcgammaRI/CD64 expression exhibited increased migratory capacity and MCP-1 production in response to LPS or CRP stimulation. Monocyte/macrophage infiltration is important in promoting mesangial hypercellularity and the development of glomerulosclerosis in both human and animal models [49,50]. Additionally, the number of infiltrating monocytes/macrophages is associated with more severe renal injury and poor prognosis in LN [50,51].
###end p 67
###begin p 68
###xml 26 28 26 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 29 31 29 31 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 32 34 32 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 341 343 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
As seen in animal models [10,26,52], monocytes expressing FcgammaRI/CD64 may be important to the pathogenesis of IC-mediated nephritis in SLE. Elevated production of IFNalpha and IFNgamma in SLE may induce the expression of FcgammaRI/CD64 monocytes and facilitate the infiltration of these cells to the sites of IC deposition in the kidney [48]. Since IFNalpha and IFNgamma also stimulate the production of monocyte attractants such as MCP-1, the presence of these cytokines in the kidney also may promote the influx of monocytes. In turn, signal transduction downstream of FcgammaRI/CD64 leads to monocyte activation and further production of inflammatory cytokines and chemokines. These events could culminate in a vicious cycle of renal inflammation and monocyte infiltration, ultimately leading to permanent tissue damage.
###end p 68
###begin title 69
Conclusion
###end title 69
###begin p 70
###xml 150 158 <span type="species:ncbi:9606">patients</span>
Our study demonstrates that elevated surface expression of FcgammaRI/CD64 is associated with ongoing systemic inflammation and renal disease in lupus patients. We propose that upregulation of FcgammaRI/CD64 expression on circulating monocytes may be a useful surrogate marker of monocyte activation in SLE.
###end p 70
###begin title 71
Abbreviations
###end title 71
###begin p 72
###xml 5 11 <span type="species:ncbi:9913">bovine</span>
BSA: bovine serum albumin; CRP: C-reactive protein; DMEM: Dulbecco's modified Eagle's medium; FcgammaR: Fcgamma receptor; IC: immune complex; IFN: interferon; IL: interleukin; LN: lupus nephritis; LPS: lipopolysaccharide; MCP-1: monocyte chemotractic protein 1; PBS: phosphate-buffered saline; SLE: systemic lupus erythematosus; TNF: tumor necrosis factor.
###end p 72
###begin title 73
Competing interests
###end title 73
###begin p 74
The authors declare that they have no competing interests.
###end p 74
###begin title 75
Authors' contributions
###end title 75
###begin p 76
###xml 295 302 <span type="species:ncbi:9606">patient</span>
###xml 437 444 <span type="species:ncbi:9606">patient</span>
###xml 532 539 <span type="species:ncbi:9606">patient</span>
###xml 630 637 <span type="species:ncbi:9606">patient</span>
WHR and HBR contributed equally to this work. YL carried out data analysis and interpretation, and the study design, and assisted in manuscript preparation. PYL participated in date analysis and interpretation, and assisted in manuscript preparation. ESS participated in acquisition of data and patient recruitment. SN participated in statistical analysis. MS assisted in data interpretation. MSS participated in acquisition of data and patient recruitment. WHR carried out the study design and data interpretation, and assisted in patient recruitment and preparation of the manuscript. HBR conceived of the study and coordinated patient recruitment, data analysis and preparation of the manuscript. All authors read and approved the final manuscript.
###end p 76
###begin title 77
Acknowledgements
###end title 77
###begin p 78
The present work was supported by grants from the National Institutes of Health (K08 DK02890 and MO1 RR00082) and the Greater Florida Chapter of the Lupus Foundation of America and the Lupus Research Institute (New York, USA). PYL is an NIH T32 trainee (DK07518). The authors thank Marlene Sarmiento, Annie Chan, Frances Reeves, Ashley Armstrong, Emily Naglich, Kate Brunner and UF GCRC staff for clinical assistance; and Barbara Kolheffer, Christopher Kennedy and Ed Butfiloski for technical assistance.
###end p 78
###begin article-title 79
Autoantibodies in systemic lupus erythematosus
###end article-title 79
###begin article-title 80
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 49 54 <span type="species:ncbi:9606">human</span>
Effects of immune complexes from SLE patients on human monocyte locomotion and Fc receptor function
###end article-title 80
###begin article-title 81
Pathogenesis of lupus nephritis: a review
###end article-title 81
###begin article-title 82
###xml 34 39 <span type="species:ncbi:9606">human</span>
Urine chemokines as biomarkers of human systemic lupus erythematosus activity
###end article-title 82
###begin article-title 83
Urinary biomarkers in lupus nephritis
###end article-title 83
###begin article-title 84
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease
###end article-title 84
###begin article-title 85
###xml 8 10 8 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 14 16 14 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
The CD14+ CD16+ blood monocytes: their role in infection and inflammation
###end article-title 85
###begin article-title 86
###xml 75 80 <span type="species:ncbi:9606">human</span>
Differential modulation of stimulatory and inhibitory Fcgamma receptors on human monocytes by Th1 and Th2 cytokines
###end article-title 86
###begin article-title 87
IgG Fc receptors
###end article-title 87
###begin article-title 88
Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis
###end article-title 88
###begin article-title 89
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Monocyte activation in patients with Wegener's granulomatosis
###end article-title 89
###begin article-title 90
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Fcgamma receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use anti-rheumatic drugs
###end article-title 90
###begin article-title 91
Monocyte receptors for the Fc portion of IgG are increased in systemic lupus erythematosus
###end article-title 91
###begin article-title 92
The 1982 revised criteria for the classification of systemic lupus erythematosus
###end article-title 92
###begin article-title 93
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE
###end article-title 93
###begin article-title 94
High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk
###end article-title 94
###begin article-title 95
Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus
###end article-title 95
###begin article-title 96
RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis
###end article-title 96
###begin article-title 97
Leukocyte-renal epithelial cell interactions regulate lupus nephritis
###end article-title 97
###begin article-title 98
Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis
###end article-title 98
###begin article-title 99
C-reactive protein: ligands, receptors and role in inflammation
###end article-title 99
###begin article-title 100
###xml 29 34 <span type="species:ncbi:9606">human</span>
Analysis of binding sites in human C-reactive protein for Fc{gamma}RI, Fc{gamma}RIIA, and C1q by site-directed mutagenesis
###end article-title 100
###begin article-title 101
C-reactive protein specifically binds to Fcgamma receptor type I on a macrophage-like cell line
###end article-title 101
###begin article-title 102
###xml 115 123 <span type="species:ncbi:9606">patients</span>
Glucocorticosteroid therapy decreases CD14-expression and CD14-mediated LPS-binding and activation of monocytes in patients suffering from systemic lupus erythematosus
###end article-title 102
###begin article-title 103
###xml 36 40 <span type="species:ncbi:10090">mice</span>
Resistance of Fc receptor-deficient mice to fatal glomerulonephritis
###end article-title 103
###begin article-title 104
###xml 57 63 <span type="species:ncbi:10090">murine</span>
FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis
###end article-title 104
###begin article-title 105
Defective Fc receptor-mediated function of the mononuclear phagocyte system in lupus nephritis
###end article-title 105
###begin article-title 106
FcgammaRIIA alleles are heritable risk factors for lupus nephritis in African Americans
###end article-title 106
###begin article-title 107
###xml 84 90 <span type="species:ncbi:10090">murine</span>
Genetic dissection of the effects of stimulatory and inhibitory IgG Fc receptors on murine lupus
###end article-title 107
###begin article-title 108
Defective mononuclear phagocyte function in systemic lupus erythematosus: dissociation of Fc receptor-ligand binding and internalization
###end article-title 108
###begin article-title 109
Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis
###end article-title 109
###begin article-title 110
Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE
###end article-title 110
###begin article-title 111
Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes
###end article-title 111
###begin article-title 112
Fc receptor genes and the systemic lupus erythematosus diathesis
###end article-title 112
###begin article-title 113
A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling
###end article-title 113
###begin article-title 114
Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts
###end article-title 114
###begin article-title 115
Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus
###end article-title 115
###begin article-title 116
###xml 70 75 <span type="species:ncbi:9606">human</span>
Glucocorticoids up-regulate constitutive interleukin-10 production by human monocytes
###end article-title 116
###begin article-title 117
###xml 58 63 <span type="species:ncbi:9606">human</span>
Time dependent production of cytokines and eicosanoids by human monocytic leukaemia U937 cells; effects of glucocorticosteroids
###end article-title 117
###begin article-title 118
Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus
###end article-title 118
###begin article-title 119
Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity
###end article-title 119
###begin article-title 120
###xml 87 91 <span type="species:ncbi:10090">mice</span>
IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice
###end article-title 120
###begin article-title 121
###xml 76 80 <span type="species:ncbi:10090">mice</span>
Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus
###end article-title 121
###begin article-title 122
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Deficiency of the type I interferon receptor protects mice from experimental lupus
###end article-title 122
###begin article-title 123
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Cytokine balance in kidney tissue from lupus nephritis patients
###end article-title 123
###begin article-title 124
Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli
###end article-title 124
###begin article-title 125
Association of anti-nucleoprotein autoantibodies with upregulation of type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus
###end article-title 125
###begin article-title 126
Cutting edge: Fc receptor type I for IgG on macrophages and complement mediate the inflammatory response in immune complex peritonitis
###end article-title 126
###begin article-title 127
Significance of leukocyte infiltration in membranous nephropathy with segmental glomerulosclerosis
###end article-title 127
###begin article-title 128
###xml 34 39 <span type="species:ncbi:9606">human</span>
Local macrophage proliferation in human glomerulonephritis
###end article-title 128
###begin article-title 129
Histologic analysis of renal leukocyte infiltration in antineutrophil cytoplasmic antibody-associated vasculitis: importance of monocyte and neutrophil infiltration in tissue damage
###end article-title 129
###begin article-title 130
Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors
###end article-title 130

